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More than 50% of all patients who present with breast cancer ulti-
mately die of the disease. The use of systemic adjuvant therapy
yields modest improvements in prognosis, which should translate
into a considerable number of lives saved, because of the high
incidence of breast cancer (Early Breast Cancer Trialists’
Collaborative Group, 1992). Other measures are, however,
required if the number of deaths is to be decreased substantially.
Research into possible methods of prevention and cure will hope-
fully yield significant benefits in the longer term. For the present,
however, earlier detection and treatment offers the best chance of
reducing mortality.
Extent of disease (stage) at diagnosis is widely recognized to be
the most important prognostic factor in patients with breast cancer.
The aim of the National Health Service Breast Screening Programme
(NHSBSP) is to detect breast cancer at a presymptomatic stage and
thus to improve survival. However, most women with breast cancer
present with symptoms (Macarthur and Smith, 1981; Burgess et al,
1998). These patients may seek medical advice soon after the
discovery of symptoms or may delay presenting to their general prac-
titioner (GP) (‘patient delay’). Delays may also occur between the
first GP visit and first hospital visit or between the first hospital visit
and treatment. The influence on survival of delays in each of these
intervals and of the influence on survival of delays between first
symptom and treatment (‘total delay’) remains contentious. Several
studies reported in the past 30 years have indicated that survival is
worse among women with longer duration of symptoms (Sheridan
et al, 1971; Wilkinson et al, 1979; Elwood and Moorehead, 1980;
Feldman et al, 1983; Charlson, 1985; Vernon et al, 1985; Huguley et
al, 1988; Machiavelli et al, 1989; Rossi et al, 1990; Neave et al, 1990;
Rabinovich et al, 1993; Afzelius et al, 1994; Raabe et al, 1996). Other
studies, however, have not shown that survival is affected by duration
of symptoms (Dennis et al, 1975; Fisher et al, 1977; Hainsworth et al,
1993) These apparently conflicting results may possibly be explained
by differences in sample characteristics (e.g. inclusion of patients
with all stages of breast cancer or restriction of the sample to patients
with operable disease only), by differences in the delay interval
studied (e.g. patient delay, delay to first hospital visit or total delay)
or by differences in the cut-offs used to define delay (e.g. 3 months
or 6 months).
A major problem with most of the previously reported studies of
the influence of delay on survival is that no account has been taken
of the potential confounding effect of lead-time bias. According to
the null hypothesis, earlier treatment confers no survival advan-
tage over later treatment among patients who present with sympto-
matic disease. The null hypothesis implies that some patients will
be long-term survivors while others will die of their disease, irre-
spective of the time of first treatment. For those who are predes-
tined to die, the interval between treatment and death will be
shorter if treatment is started later in the course of the disease. An
apparent adverse influence of delay on survival could thus be
attributable to this lead-time effect if survival is measured from the
time of diagnosis. Measurement of survival from the time that
a patient first notices symptoms, rather than from the time of
diagnosis (as is conventionally reported), addresses this issue.
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Summary The aim of this study was to examine the possible influence on survival of delays prior to presentation and/or treatment among
women with breast cancer. Duration of symptoms prior to hospital referral was recorded for 2964 women who presented with any stage of
breast cancer to Guy’s Hospital between 1975 and 1990. Median follow-up is 12.5 years. The impact of delay (defined as having symptoms
for 12 or more weeks) on survival was measured from the date of diagnosis and from the date when the patient first noticed symptoms to
control for lead-time bias. Thirty-two per cent (942/2964) of patients had symptoms for 12 or more weeks before their first hospital visit and
32% (302/942) of patients with delays of 12 or more weeks had locally advanced or metastatic disease, compared with only 10% (210/2022)
of those with delays of less than 12 weeks (P < 0.0001). Survival measured both from the date of diagnosis (P < 0.001) and from the onset of
the patient’s symptoms (P = 0.003) was worse among women with longer delays. Ten years after the onset of symptoms, survival was 52%
for women with delays less than 12 weeks and 47% for those with longer delays. At 20 years the survival rates were 34% and 24%
respectively. Furthermore, patients with delays of 12–26 weeks had significantly worse survival rates than those with delays of less than 12
weeks. Multivariate analyses indicated that the adverse impact of delay in presentation on survival was attributable to an association between
longer delays and more advanced stage. However, within individual stages, longer delay had no adverse impact on survival. Analyses based
on ‘total delay’ (i.e. the interval between a patient first noticing symptoms and starting treatment) yielded very similar results in terms of
survival to those based on delay to first hospital visit (delay in presentation).
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In this study, we have assessed the relationship between dura-
tion of symptoms and survival among almost 3000 women
managed in a single institution between 1975 and 1990. Our
primary hypothesis was that, when all patients presenting with
breast cancer are considered, those with duration of symptoms of
at least 12 weeks would have worse survival rates than those with
shorter delays. A number of secondary hypotheses were also
defined: first, that patients with longer duration of symptoms
would in general present with more advanced disease and that this
relationship between delay and stage would account for the poorer
survival in patients with longer delays; and, second, that for
patients within any individual tumour stage longer delays would
have no detrimental effect on survival. To illustrate this, consider
two patients, each presenting with a 1.5-cm, node-negative (stage
I) cancer, one of whom has had a 2-week delay, the other a 9-
month delay. According to this secondary hypothesis the patient
with the 9-month delay would have at least as good a prognosis as
the patient with the shorter delay. This effect has previously been
reported for patients with stage I cancer (Sheridan, 1971;
Wilkinson, 1979; Charlson, 1985) and for patients with stage III
tumours (Rubens et al, 1977).
METHODS
Patients
Computerized records of all patients with breast cancer who were
referred directly to the breast unit at Guy’s Hospital between 1
January 1975 and 31 December 1990 were reviewed. Patients who
had initially been diagnosed elsewhere and had subsequently been
referred to the unit for further management were excluded. The
study period was selected because uniform criteria for histological
assessment and staging had been used throughout. The end date of
the study was chosen to give a minimum of 5 years’ follow-up for
all patients. In addition, virtually all patients presented sympto-
matically during this period, whereas more recently a significant
number of patients have presented via the NHSBSP.
Data collection
At the time of the first hospital visit all patients were asked to
complete a proforma, which included a question on duration of
symptoms. Other factors retrieved from the computer database
included date of first hospital attendance, date of diagnosis, date of
first definitive treatment, age and menopausal status at diagnosis,
date of last follow-up and date of death (where applicable).
Information on clinical tumour size, histological type and grade
(Bloom and Richardson, 1957), pathological axillary node status
and stage was also extracted from the database. The staging classi-
fication used was as follows:
stage I – operable disease with pathologically negative axillary
nodes;
stage II – operable disease with pathologically positive nodes;
stage III – locally advanced, inoperable disease;
stage IV – metastatic disease at presentation.
Management
Standardized protocols for the assessment and treatment of breast
cancer were used within the unit throughout the study period,
although these evolved over time. Where appropriate, patients
were entered into clinical trials related to the management of the
primary tumour (van Dongen et al, 1991) and to the use of
systemic therapies (Rubens et al, 1980, 1983, 1989; Nolvadex
Adjuvant Trial Organisation, 1988; Richards et al, 1990; Scottish
Cancer Trials Breast Group, 1993; Fentiman et al, 1994). In over
90% of all operable cases, histological assessment of axillary
lymph node status was undertaken, usually following full axillary
dissection.
Statistical analysis
Two delay intervals were examined for the analyses of the influ-
ence of delay on survival. The first was the interval between a
patient first noticing symptoms (onset of symptoms) and the first
visit to the hospital (defined as ‘delay in presentation’). The
second was the interval between onset of symptoms and first
definitive treatment (defined as ‘total delay’). For each of these
analyses, arbitrary cut-off points of 12 weeks and 26 weeks were
used to define different delay groups for comparability with other
reported studies. Patients for whom the recorded duration of symp-
toms at first hospital visit was either ‘3 months’ or ‘6 months’
were included in the 12–26 week group for the analysis of delay in
presentation. Possible relationships between delay and other
factors were assessed using the chi-squared test.
The log rank test was used to assess the influence on survival of
delay in presentation and total delay in univariate analyses.
Table 1 Proportion of patients experiencing delays in presentation and/or treatment
Onset of symptoms First hospital visit Onset of symptoms
to first hospital visit to treatment to treatment
n (%) n (%) n (%)
< 1 week 284 (10) 1496 (51) 36 (1)
1–2 weeks 407 (14) 661 (23) 152 (5)
2–3 weeks 291 (10) 338 (12) 282 (10)
3–4 weeks 349 (12) 176 (6) 288 (10)
4–8 weeks 572 (19) 238 (8) 822 (28)
8–12 weeks 119 (4) 21 (1) 372 (13)
12–26 weeks 529 (18) 3 (<1) 491 (17)
26–52 weeks 211 (7) 1 (<1) 204 (7)
> 52 weeks 202 (7) 3 (<1) 290 (10)
Total 2964 2937 2937860 MA Richards et al
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Survival was measured in two ways: first, from the date of histo-
logical diagnosis and, second, from the calculated date of onset of
symptoms. The survival analyses relate to all-cause mortality
unless otherwise specified.
Multivariate analyses were undertaken using the stepwise Cox
regression model with survival from diagnosis and from onset of
symptoms as the outcome measures. Age, duration of symptoms
prior to first hospital visit, grade and menopausal status (1–5 years
post-menopausal vs other) were first included in the model.
Similar results were obtained when duration of symptoms was
considered as a continuous variable and when the cut-off of 12
weeks was applied. A second set of analyses was undertaken,
including clinical tumour size and stage in the model.
RESULTS
A total of 3099 women with primary breast cancer were referred
directly to the unit over the 16-year period of the study.
Prospectively recorded information on duration of symptoms prior
to first hospital visit was available for 2964 (96%) of these women.
No difference in survival was observed between those with or
without data on duration of symptoms (P = 0.09). Median survival
was 9.5 years. Dates of first hospital visit and date of first treat-
ment were available in 2937 cases (99%). The proportions of
patients experiencing different delays prior to presentation,
between presentation and treatment and total delays are shown in
Table 1.
Relationship between delay in presentation and tumour
characteristics
The relationships between duration of symptoms prior to first
hospital visit and other demographic or tumour-related factors are
shown in Table 2. Delay was highly significantly related to age,
tumour size and stage. Patients over 65 years of age tended to have
longer duration of symptoms (P < 0.0001). Among patients with
tumours measuring 2 cm or less in diameter, only 196/860 (23%)
delayed for 12 weeks or more compared with 466/1592 (29%) of
patients with tumours between 2 and 5 cm and 245/448 (55%) of
patients with tumours more than 5 cm in diameter (P < 0.0001).
Only 640/2452 (26%) of patients with operable disease had symp-
toms for 12 weeks or more, compared with 302/512 (59%) of
patients with locally advanced or metastatic disease (P < 0.0001).
Table 2 Patient and tumour characteristics according to duration of
symptoms prior to first hospital visit
< 12 weeks ³ 12 weeks
n (%) n %
Age
<35 74 (4%) 31 (3%)
35–49 555 (27%) 212 (23%)
50–64 841 (42%) 376 (40%)
65–74 420 (21%) 231 (25%)
75+ 132 (7%) 92 (10%)
Tumour sizea
≤ 2 cm 664 (33%) 196 (22%)
> 2 cm and ≤ 5 cm 1126 (56%) 466 (51%)
> 5 cms 203 (10%) 245 (27%)
Unknown 29 35
Stageb
Operable N0 880 (44%) 281 (30%)
Operable N+ 783 (39%) 290 (31%)
Operable N? 149 (7%) 69 (7%)
Locally advanced 161 (8%) 201 (21%)
Metastatic 49 (2%) 101 (11%)
Histology
Ductal I 130 (6%) 66 (7%)
Ductal II 748 (37%) 377 (40%)
Ductal III 615 (30%) 230 (24%)
Lobular 218 (11%) 105 (11%)
Other 311 (15%) 164 (17%)
Year of diagnosis
1975–78 460 (23%) 212 (23%)
1979–82 536 (27%) 242 (26%)
1983–86 501 (25%) 277 (29%)
1987–90 525 (26%) 211 (22%)
Total 2022 (68%) 942 (32%)
aTumour size was measured clinically at the time of first hospital visit. bNodal
status was categorized as follows: N0, No pathological axillary node
involvement. N+, Pathological axillary node involvement. N?, Axillary nodes
not examined pathologically.




































































Figure 1 Survival measured from date of diagnosis, all patients. (a) Delay
< 12 weeks (n = 2022). (b) Delay 12–26 weeks (n = 691). (c) Delay
> 26 weeks (n = 413). P < 0.0001
Figure 2 Survival measured from onset of symptoms, all patients. (a) Delay
< 12 weeks (n = 2022). (b) Delay 12–26 weeks (n = 691). (c) Delay > 26
weeks (n = 413). P = 0.003Delay and survival from breast cancer 861
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Patients with ductal grade III tumours had significantly shorter
periods of delay than others (P < 0.001). Duration of symptoms
did not change significantly over the course of the study period.
Among patients with duration of symptoms prior to first
hospital visit of less than 12 weeks, an earlier cut-off (4 weeks)
was also examined. No significant differences in the distribution
of demographic or tumour characteristics were observed between
patients with a delay of 4 weeks or less and those with a delay
longer than 4 weeks but less than 12 weeks (data not shown).
Survival measured from date of diagnosis
Survival measured from the date of diagnosis according to delay in
presentation is shown in Figure 1. Longer delay in presentation
was significantly associated with worse survival (P < 0.0001). At
10 years following diagnosis the all-cause survival rates for
different delay groups were as follows: 51% (delay < 12 weeks);
44% (delay 12–26 weeks) and 40% (delay > 26 weeks). At 20
years, the survival rates were 33%, 26% and 24% respectively.
Thus, a 7% difference in survival between those with short (< 12
weeks) and intermediate (12–26 weeks) delays was observed both
at 10 years and at 20 years. When breast cancer mortality only was
considered, the comparable survival rates at 10 years were 58%,
51% and 47% respectively, and those at 20 years were 48%, 40%
and 32% respectively.
Survival measured from onset of symptoms
Survival measured from the calculated date of onset of symptoms
according to delay in presentation is shown in Figure 2. The
impact of delay in presentation on survival remains highly signifi-
cant (P = 0.003), but the curves only start to diverge markedly
after about 4 years. At 10 years from onset of symptoms a 5%
difference in survival was observed between patients with delays
of less or more than 12 weeks (52% vs 47%). At 20 years, the
difference in survival was 10% (34% vs 24%). Again, when deaths
from causes other than breast cancer were excluded, similar
survival differences according to delay were observed. At 10
years, the survival rates were 57% and 53% respectively, and at 20
years they were 48% and 33%.
Subanalyses by stage and grade
Because of the influence of delay on stage, additional analyses
were undertaken to assess the influence of delay in presentation on
survival within each stage. When survival was measured from the








































































































































Figure 3 Survival measured from onset of symptoms (A) Stage I. (a) Delay < 12 weeks (n = 880). (b) Delay > 12 weeks (n = 281). P = 0.1. (B) Stage II. (a)
Delay < 12 weeks (n = 880). (b) Delay ³ 12 weeks (n = 281). P = 0.03. (C) Stage III. (a) Delay < 12 weeks (n = 161). (b) Delay ³ 12 weeks (n = 201). P < 0.02.
(D) Stage IV. (a) Delay < 12 weeks (n = 49). (b) Delay ³ 12 weeks (n = 101). P < 0.001.862 MA Richards et al
British Journal of Cancer (1999) 79(5/6), 858–864 © Cancer Research Campaign 1999
date of diagnosis those with longer delays within each stage tended
to have better survival, though none of the differences reached
significance. When survival was measured from the onset of
symptoms, these trends were more marked and reached signifi-
cance among patients in stages II (P = 0.01), III (P = 0.001) and IV
(P ≤ 0.001) (Figure 3).
Because of the finding that patients with grade III tumours
presented significantly earlier than others, the impact of delay
within each tumour grade was assessed. For patients with ductal
carcinomas, delays of 12 or more weeks in presentation had
an adverse impact on survival in each tumour grade (grade I,
P = 0.05; grade II, P = 0.001; grade III, P = 0.007).
Multivariate analyses
The results of multivariate analyses of factors influencing survival
from diagnosis and from onset of symptoms are shown in Tables 3
and 4. In the first analyses (Table 3), only grade, duration of symp-
toms, menopausal status and age were entered into the model (i.e.
factors related to the extent of disease were excluded). Longer
duration of symptoms had a highly significant adverse influence
on survival in this model (P < 0.0001). When tumour size and
stage were included in the model (Table 4) the adverse influence of
longer duration of symptoms was no longer apparent. Indeed the
hazard ratios for duration of symptoms indicate that longer dura-
tion of symptoms is a beneficial factor in these circumstances.
These findings are in keeping with the effect of delay within each
stage observed in the univariate analyses.
The influence of ‘total delay’ on survival
The influence of total delay on survival was assessed by adding the
interval between first hospital visit and first treatment for each
patient to the recorded duration of symptoms at the time of first
hospital visit. As shown in Figure 4 the survival pattern for groups
of patients with different total delay intervals is similar to that
observed for delay in presentation (Figure 1).
DISCUSSION
This is the largest single institution study of delay and survival
from breast cancer in the UK and, to the best of our knowledge, in
the world. The findings of this study strongly support the primary
hypothesis that longer duration of symptoms is associated with
worse survival rates. Our findings are consistent with the
consensus in the literature that longer delays are associated with
larger tumour sizes (Fisher et al, 1977; GIVIO, 1986; Neave et al,
1990; Rossi et al, 1990) and with more advanced stage (Wilkinson
et al, 1979; Elwood and Moorehead, 1980; GIVIO, 1986;
Machiavelli et al, 1989; Rossi et al, 1990). In keeping with a large,
multicentre study from Denmark, we found that longer duration of
symptoms is associated with older age (Afzelius et al, 1994).
Others have reported, however, that delay is associated with
younger age (Machiavelli et al, 1989; Richardson et al, 1992).
Table 4 Multivariate analyses of factors influencing survival, including
factors related to extent of disease (tumour size and stage)
Variable Hazard ratio 95% CI P-value
Survival measured from histological
diagnosis
Stage 1.62 1.55–1.70 < 0.0001
Grade 1.54 1.40–1.69 < 0.0001
Menopausal status 1.36 1.16–1.59 < 0.0001
Tumour size 1.09 1.07–1.12 < 0.0001
Age 1.02 1.01–1.02 < 0.0001
Duration of symptoms 0.87 0.77–0.97 0.01
Survival measured from onset of
symptoms
Stage 1.60 1.52–1.68 < 0.0001
Grade 1.55 1.42–1.70 < 0.0001
Menopausal status 1.40 1.20–1.64 < 0.0001
Tumour size 1.07 1.05–1.10 < 0.0001
Age 1.02 1.01–1.02 < 0.0001
Duration of symptoms 0.72 0.64–0.81 < 0.0001
The hazard ratios indicate that, once the adverse impact of stage on survival
has been accounted for, longer duration of symptoms is a beneficial rather
than an adverse prognostic factor.
Table 3 Multivariate analyses of factors influencing survival, excluding
factors related to extent of disease (tumour size and stage)
Variable Hazard ratio 95% CI P-value
Survival measured from histological
diagnosis
Grade 1.65 1.51–1.81 < 0.0001
Duration of symptoms 1.31 1.18–1.45 < 0.0001
Menopausal status 1.36 1.16–1.59 < 0.0001
Age 1.03 1.02–1.03 < 0.0001
Survival measured from onset of
symptoms
Grade 1.66 1.52–1.82 < 0.0001
Duration of symptoms 1.15 1.04–1.27 < 0.0001
Menopausal status 1.37 1.17–1.59 < 0.0001
Age 1.03 1.02–1.03 < 0.0001
Factors directly related to extent of disease (e.g. tumour size and stage)
were excluded from this analysis. The hazard ratios indicate that in this
analysis longer duration of symptoms is associated with worse survival rates
and that this effect is independent of tumour grade, menopausal status and
age.


































Figure 4 Influence of ‘total delay’ on survival. (a) Delay < 12 weeks
(n = 1952). (b) Delay 12–26 weeks (n = 491). (c) Delay > 26 weeks (n = 494).
P < 0.001Delay and survival from breast cancer 863
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The impact of delay on survival measured from the onset of
symptoms has only rarely been assessed. Elwood and Moorehead
(1980) examined cohorts of women diagnosed in Vancouver
between 1945 and 1975. As with the current study, they showed
that longer delays adversely affect survival not only when survival
is measured from the date of diagnosis but also when survival is
measured from the onset of symptoms. This finding is of consider-
able importance as it demonstrates that the impact of delay is not
solely due to a lead-time bias (i.e. the adverse influence on
survival of delays before presentation/treatment cannot simply be
attributed to patients being further from the point of onset of
symptoms and thus inevitably closer to the time of death).
The findings from this study indicate that patients with longer
delays before their first hospital visit (either because of their own
delay or because of delay in referral to hospital) tend to have
tumours that are of a more advanced stage. The cancers in patients
experiencing longer delays are, if anything, less biologically
aggressive, as measured by the histological grade of the tumour,
than those in women with shorter delays. However, the
subanalyses by tumour grade show that longer delays are associ-
ated with worse survival rates irrespective of tumour grade. The
multivariate analyses indicate that longer delays have an adverse
impact on survival, which can be attributed to the more advanced
stage of disease at presentation.
Within each stage, patients with longer delays had similar or
better survival than those who presented within 12 weeks of the
onset of symptoms. A plausible explanation for this is that tumours
that do not progress to a more advanced stage despite delays are
intrinsically less aggressive than the average for that stage. This
may also help to explain some of the apparently contradictory
findings in the literature. Reports published since 1970 that have
shown no significant relationship between delay and survival have
generally been confined to patients with early stage (operable)
disease (Alderson et al, 1971; Dennis et al, 1975; Wallgren et al,
1976; Fisher et al, 1977).
The association between delays of 12 weeks or more and worse
long-term survival rates measured from the onset of symptoms
may have implications for malpractice litigation. The number of
cases of breast cancer that result in litigation related to provider-
mediated delays in diagnosis appears to be increasing markedly. In
the USA, the costs of such litigation cases are now second only to
those associated with injuries sustained in newborn children
(Kern, 1994). Analysis of the shape of the survival curves in the
current study (Figure 2) suggests that, in general, deaths that occur
within the first few years of the onset of symptoms are unlikely to
be related to delays in presentation or diagnosis of 12 or more
weeks. Later deaths may, however, be attributable to such delays,
particularly if the delay has resulted in progression of the disease
to a more advanced stage.
The relationship between delay and outcome suggests that the
long-term survival rates for women who present with symptomatic
breast cancer could be improved if effective strategies could be
developed to reduce delays in presentation and/or treatment. The
data available for this study relate to the period between first detec-
tion of a symptom and first hospital visit and between first hospital
visit and treatment. It was not possible to define the relative contri-
butions of patient or general practitioner delay. If effective strate-
gies are to be developed to reduce overall delay, it will be important
to identify more closely groups of patients at high risk of delay, so
that interventions (e.g. educational programmes) can be appropri-
ately targeted. Studies from the USA have indicated that patients
from ethnic minority groups (Fisher et al, 1977; Vernon et al, 1985;
Richardson et al, 1992) and those who are socioeconomically
disadvantaged (Richardson et al, 1992) are more likely to experi-
ence delay. The underlying reasons for delay in terms of psycho-
logical and social factors are poorly understood (Facione, 1993).
Recent evidence suggests that patients whose initial symptoms do
not include a lump are more likely to delay seeking medical advice
and that patients who do present to their GP with symptoms other
than a lump are more likely to experience a delay in onward referral
(Burgess et al, 1998).
We are currently undertaking a systematic review of the litera-
ture related to delay in the diagnosis of symptomatic breast cancer.
In addition to clarifying the evidence related to the impact of delay
on stage and survival, the review will examine the evidence related
to factors that determine patient and provider delay. The outcome
of this review will inform the design of prospective studies to
define who is most at risk of delay and why delays occur.
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